We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

A la carte

10 November 2003 By Robert Cyran

The Swiss biotechnology company is issuing a $440m convertible to fund its expansion plans outside Switzerland. With $2.2bn in cash, Serono can afford to buy struggling competitors or their products. But Serono has already missed the real bargains.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)